183 related articles for article (PubMed ID: 36842439)
1. Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.
You R; Liu YP; Xie YL; Lin C; Duan CY; Chen DP; Pan Y; Qi B; Zou X; Guo L; Cao JY; Zhang YN; Wang ZQ; Liu YL; Ouyang YF; Wen K; Yang Q; Xie RQ; Li HF; Duan XT; Ding X; Peng L; Chen SY; Liang JL; Feng ZK; Xia TL; Xie RL; Jiang R; Gu CM; Liu RZ; Sun R; Yang X; Liu LZ; Ling L; Liu Q; Ng WT; Hua YJ; Huang PY; Chen MY
Lancet; 2023 Mar; 401(10380):917-927. PubMed ID: 36842439
[TBL] [Abstract][Full Text] [Related]
2. Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial.
Liu YP; Wen YH; Tang J; Wei Y; You R; Zhu XL; Li J; Chen L; Ling L; Zhang N; Zou X; Hua YJ; Chen YM; Chen L; Lu LX; Chen MY; Wen WP
Lancet Oncol; 2021 Mar; 22(3):381-390. PubMed ID: 33600761
[TBL] [Abstract][Full Text] [Related]
3. Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial.
Liu LT; Liu H; Huang Y; Yang JH; Xie SY; Li YY; Guo SS; Qi B; Li XY; Chen DP; Jin F; Sun XS; Yang ZC; Liu SL; Luo DH; Li JB; Liu Q; Wang P; Guo L; Mo HY; Qiu F; Yang Q; Liang YJ; Jia GD; Wen DX; Yan JJ; Zhao C; Chen QY; Sun R; Tang LQ; Mai HQ
Lancet Oncol; 2023 Jul; 24(7):798-810. PubMed ID: 37290468
[TBL] [Abstract][Full Text] [Related]
4. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial.
Tang LQ; Chen DP; Guo L; Mo HY; Huang Y; Guo SS; Qi B; Tang QN; Wang P; Li XY; Li JB; Liu Q; Gao YH; Xie FY; Liu LT; Li Y; Liu SL; Xie HJ; Liang YJ; Sun XS; Yan JJ; Wu YS; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Lv X; Wang L; Xia WX; Zhao C; Cao KJ; Qian CN; Guo X; Hong MH; Nie ZQ; Chen QY; Mai HQ
Lancet Oncol; 2018 Apr; 19(4):461-473. PubMed ID: 29501366
[TBL] [Abstract][Full Text] [Related]
5. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
Lv X; Cao X; Xia WX; Liu KY; Qiang MY; Guo L; Qian CN; Cao KJ; Mo HY; Li XM; Li ZH; Han F; He YX; Liu YM; Wu SX; Bai YR; Ke LR; Qiu WZ; Liang H; Liu GY; Miao JJ; Li WZ; Lv SH; Chen X; Zhao C; Xiang YQ; Guo X
Lancet Oncol; 2021 May; 22(5):716-726. PubMed ID: 33857411
[TBL] [Abstract][Full Text] [Related]
6. Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial.
Tang LL; Huang CL; Zhang N; Jiang W; Wu YS; Huang SH; Mao YP; Liu Q; Li JB; Liang SQ; Qin GJ; Hu WH; Sun Y; Xie FY; Chen L; Zhou GQ; Ma J
Lancet Oncol; 2022 Apr; 23(4):479-490. PubMed ID: 35240053
[TBL] [Abstract][Full Text] [Related]
7. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.
Sun Y; Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J
Lancet Oncol; 2016 Nov; 17(11):1509-1520. PubMed ID: 27686945
[TBL] [Abstract][Full Text] [Related]
8. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.
Chen YP; Liu X; Zhou Q; Yang KY; Jin F; Zhu XD; Shi M; Hu GQ; Hu WH; Sun Y; Wu HF; Wu H; Lin Q; Wang H; Tian Y; Zhang N; Wang XC; Shen LF; Liu ZZ; Huang J; Luo XL; Li L; Zang J; Mei Q; Zheng BM; Yue D; Xu J; Wu SG; Shi YX; Mao YP; Chen L; Li WF; Zhou GQ; Sun R; Guo R; Zhang Y; Xu C; Lv JW; Guo Y; Feng HX; Tang LL; Xie FY; Sun Y; Ma J
Lancet; 2021 Jul; 398(10297):303-313. PubMed ID: 34111416
[TBL] [Abstract][Full Text] [Related]
9. Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trial.
Mao YP; Wang SX; Gao TS; Zhang N; Liang XY; Xie FY; Zhang Y; Zhou GQ; Guo R; Luo WJ; Li YJ; Liang SQ; Lin L; Li WF; Liu X; Xu C; Chen YP; Lv JW; Huang SH; Liu LZ; Li JB; Tang LL; Chen L; Sun Y; Ma J
BMJ; 2023 Feb; 380():e072133. PubMed ID: 36746459
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.
Zhang L; Huang Y; Hong S; Yang Y; Yu G; Jia J; Peng P; Wu X; Lin Q; Xi X; Peng J; Xu M; Chen D; Lu X; Wang R; Cao X; Chen X; Lin Z; Xiong J; Lin Q; Xie C; Li Z; Pan J; Li J; Wu S; Lian Y; Yang Q; Zhao C
Lancet; 2016 Oct; 388(10054):1883-1892. PubMed ID: 27567279
[TBL] [Abstract][Full Text] [Related]
11. Hyperfractionation compared to standard fractionation in intensity-modulated radiation therapy for patients with locally advanced recurrent nasopharyngeal carcinoma.
Lee VH; Kwong DL; Leung TW; Ng SC; Lam KO; Tong CC; Sze CK
Eur Arch Otorhinolaryngol; 2017 Feb; 274(2):1067-1078. PubMed ID: 27738820
[TBL] [Abstract][Full Text] [Related]
12. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Chen L; Hu CS; Chen XZ; Hu GQ; Cheng ZB; Sun Y; Li WX; Chen YY; Xie FY; Liang SB; Chen Y; Xu TT; Li B; Long GX; Wang SY; Zheng BM; Guo Y; Sun Y; Mao YP; Tang LL; Chen YM; Liu MZ; Ma J
Lancet Oncol; 2012 Feb; 13(2):163-71. PubMed ID: 22154591
[TBL] [Abstract][Full Text] [Related]
13. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
[TBL] [Abstract][Full Text] [Related]
14. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
[TBL] [Abstract][Full Text] [Related]
15. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
Gillison ML; Trotti AM; Harris J; Eisbruch A; Harari PM; Adelstein DJ; Jordan RCK; Zhao W; Sturgis EM; Burtness B; Ridge JA; Ringash J; Galvin J; Yao M; Koyfman SA; Blakaj DM; Razaq MA; Colevas AD; Beitler JJ; Jones CU; Dunlap NE; Seaward SA; Spencer S; Galloway TJ; Phan J; Dignam JJ; Le QT
Lancet; 2019 Jan; 393(10166):40-50. PubMed ID: 30449625
[TBL] [Abstract][Full Text] [Related]
16. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial.
Wang SL; Fang H; Song YW; Wang WH; Hu C; Liu YP; Jin J; Liu XF; Yu ZH; Ren H; Li N; Lu NN; Tang Y; Tang Y; Qi SN; Sun GY; Peng R; Li S; Chen B; Yang Y; Li YX
Lancet Oncol; 2019 Mar; 20(3):352-360. PubMed ID: 30711522
[TBL] [Abstract][Full Text] [Related]
18. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
19. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial.
Erlandsson J; Holm T; Pettersson D; Berglund Å; Cedermark B; Radu C; Johansson H; Machado M; Hjern F; Hallböök O; Syk I; Glimelius B; Martling A
Lancet Oncol; 2017 Mar; 18(3):336-346. PubMed ID: 28190762
[TBL] [Abstract][Full Text] [Related]
20. Effect of total dose and fraction size on survival of patients with locally recurrent nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: a phase 2, single-center, randomized controlled trial.
Tian YM; Zhao C; Guo Y; Huang Y; Huang SM; Deng XW; Lin CG; Lu TX; Han F
Cancer; 2014 Nov; 120(22):3502-9. PubMed ID: 25056602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]